Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Biochemie     Collection: Cellular Biochemistry (F.-U. Hartl)     Display Documents



ID: 39018.0, MPI für Biochemie / Cellular Biochemistry (F.-U. Hartl)
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases
Authors:Warmuth, M.; Simon, N.; Mitina, O.; Mathes, R.; Fabbro, D.; Manley, P. W.; Buchdunger, E.; Forster, K.; Moarefi, I.; Hallek, M.
Language:English
Date of Publication (YYYY-MM-DD):2003-01-15
Title of Journal:Blood
Journal Abbrev.:Blood
Volume:101
Issue / Number:2
Start Page:664
End Page:672
Review Status:Peer-review
Audience:Not Specified
Abstract / Description:The leukemogenic tyrosine kinase Bcr-AbI contains a highly conserved inhibitor-binding pocket (IBP), which serves as a binding site for imatinib mesylate. Mutations at the IBP may lead to resistance of the AbI kinase against imatinib mesylate. To examine the mechanisms of imatinib mesylate binding and resistance in more detail, we created several point mutations at amino acid positions 315 and 380 of AbI, blocking the access to the IBP and rendering Bcr-AbI imatinib mesylate-resistant. Moreover, introduction of a mutation destabilizing the inactive conformation of AbI (Asp276Ser/GIu279Ser) also led to imatinib mesylate resistance, suggesting that the inhibitor required inactivation of the kinase prior to binding. These Bcr-AbI mutants were then used to evaluate the binding mode and specificity of 2 compounds, PP1 and CGP76030, originally characterized as Src kinase inhibitors. Both compounds inhibited Bcr-AbI in a concentration-dependent manner by overlapping binding modes. However, in contrast to imatinib mesylate, PP1 and CGP76030 blocked cell growth and survival in cells expressing various inhibitor-resistant AbI mutants. Studies on the potential signaling mechanisms demonstrated that in cells expressing inhibitor-resistant Bcr-AbI mutants, PP1 and CGP76030 inhibited the activity of Src family tyrosine kinases and Akt but not signal transducer and activator of transcription-5 (STAT5) and JUN kinase (Jnk). The results suggest that the use of Src kinase inhibitors is a potential strategy to prevent or overcome clonal evolution of imatinib mesylate resistance in Bcr-AbI(+) leukemia. (C) 2003 by The American Society of Hematology.
Comment of the Author/Creator:Date: 2003, JAN 15
External Publication Status:published
Document Type:Article
Communicated by:N.N.
Affiliations:MPI für Biochemie
External Affiliations:Univ Munich, Med Klin 3, Marchioninistr 15, D-81377 Munich,; Germany; GSF Forschungszentrum Umwelt & Gesundheit, Klin Kooperat Grp Gentherapie, Munich, Germany; Univ Munich, Klinikum Grosshadern, Med Klin 3, D-8000 Munich, Germany; Novartis Pharma, Oncol Res, Basel, Switzerland; Univ Munich, Genzentrum, Munich, Germany
Identifiers:ISI:000180384800042 [ID No:1]
ISSN:0006-4971 [ID No:2]
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.